Digest Network Come funziona
Network
/
Società
Ge
Non verificato

Genentech

Di cosa scriviamo

BiotecnologiaFarmaceuticaIndustriaMedicina - VarieSalute

81 comunicati stampa

Guarda tutti i comunicati
24/04/2026
Genentech Partners With Comedy Icon Damon Wayans and diaTribe to Address Diabetes-Related Vision Loss With ‘All Eyes on DME’ Campaign
Fonte
Genentech
Emittente
Business Wire
1.00
0
21/04/2026
Eventi
Industria
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Genentech’s Fenebrutinib Significantly Reduced Relapses Versus Standard of Care to Approximately One Every 17 Years in RMS
Fonte
Genentech
Emittente
Business Wire
1.00
0
21/04/2026
Industria
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Genentech’s Enspryng (Satralizumab) Reduces Risk of Relapses by 68% Demonstrating Potential to Become First Treatment for MOGAD
Fonte
Genentech
Emittente
Business Wire
1.00
0
21/04/2026
Eventi
Fiere
Industria
Salute
Igiene alimentare
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
CORRECTING and REPLACING FDA Accepts Application for Genentech’s Gazyva for the Treatment of the Most Common Form of Lupus
Fonte
Genentech
Emittente
Business Wire
1.00
0
21/04/2026
Eventi
Fiere
Industria
Salute
Igiene alimentare
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
FDA Accepts Application for Genentech’s Gazyva for the Treatment of the Most Common Form of Lupus
Fonte
Genentech
Emittente
Business Wire
1.00
0
09/03/2026
Industria
Scienza
Igiene alimentare
Medicina - Varie
Biotecnologia
Farmaceutica
Vetrine/Shopping
Salute
Oncologia
Genentech Provides Update on Phase III persevERA Study in ER-positive Advanced Breast Cancer
Fonte
Genentech
Emittente
Business Wire
1.00
0
06/03/2026
Industria
Biotecnologia
Farmaceutica
Salute
Medicina - Varie
New England Journal of Medicine Publishes Phase III ALLEGORY Data Showing Genentech’s Gazyva Significantly Reduces Disease Activity in the Most Common Form of Lupus
Fonte
Genentech
Emittente
Business Wire
1.00
0
05/03/2026
Industria
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Genentech Announces Positive Phase II Results for Petrelintide, an Amylin Analog Developed for People Living With Overweight and Obesity
Fonte
Genentech
Emittente
Business Wire
1.00
0
02/03/2026
Industria
Salute
Sanità
Medicina - Varie
Farmaceutica
Biotecnologia
Genentech's Fenebrutinib Confirms Its Potential as First and Only BTK Inhibitor for Relapsing and Primary Progressive MS in Third Positive Phase III Study (FENhance 1)
Fonte
Genentech
Emittente
Business Wire
1.00
0
20/02/2026
Industria
Oncologia
Salute
Igiene alimentare
Sanità
Medicina - Varie
Farmaceutica
Biotecnologia
FDA Approves Genentech’s Venclexta® Plus Acalabrutinib Combination Regimen for Previously Untreated Chronic Lymphocytic Leukemia
Fonte
Genentech
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0